The FDA has approved Durezol (difluprednate ophthalmic emulsion 0.05%, from Sirion), a topical steroid for the treatment of postoperative ocular inflammation and pain. This approval was based on results from two clinical trials which showed reductions in postoperative inflammation and pain after intraocular surgery with Durezol when compared to placebo.

Durezol is expected to be available in late 2008.

For more information call (813) 496-7325 or visit www.siriontherapeutics.com.